Browsing by Author "Ferrés Garrido, Marcela Viviana"

Now showing 1 - 20 of 35
  • Thumbnail Image
    Item
    A rapid method for infectivity titration of Andes hantavirus using flow cytometry
    (2013) Barriga, Gonzalo P.; Martínez Valdebenito, Constanza; Galeno, Héctor; Ferrés Garrido, Marcela Viviana; Lozach, Pierre Yves; Tischler, Nicole D.
  • Thumbnail Image
    Item
    Ampliación del rango de distribución de Oligoryzomys longicaudatus (Rodentia, Sigmodontinae) en la Patagonia de Chile y primer registro de Hantavirus en la región
    (2009) Belmar Lucero, Sebastián Antoni; Godoy Moraga, Paula Roxana.; Ferrés Garrido, Marcela Viviana; Palma Vásquez, Ramón Eduardo
  • Thumbnail Image
    Item
    Andes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile
    (2010) Torres Pérez, Fernando; Palma Vásquez, Ramón Eduardo; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Caracterización clínica y epidemiológica de infección asociada a atención en salud por virus influenza en pacientes críticos
    (2019) Gutiérrez, Valentina; Cerda, Jaime; Le Corre Pérez, Monique Nicole; Medina, Rafael; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Consenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Primera parte
    (2019) Cerón Araya, Inés María; Gambra, Pilar; Vizcaya Altamirano, María Cecilia; Ferrés Garrido, Marcela Viviana; Bidart, Teresa; López Quizhpi, Tania Lorena; Acuña, M. Paz; Álvarez, Ana M.; Zubieta, Marcela; Rabello, Marcela; Iruretagoyena Bruce, Mirentxu Inés; Rabagliati Borie, Ricardo Miguel
    The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of two manuscripts. This first part details the risks of developing infectious complications depending on the type of biological used for a certain pathology. This evaluation included a broad search in MEDLINE and Epistemonikos of systematic reviews and meta-analyzes of controlled clinical trials and case- control examining post-treatment infections with anti-TNF alpha, anti-CD20, anti-CD52, CTLA4-Ig and anti-integrins. The research was complemented by a review of: multicentre cohorts of biological users, the MMWR of the CDC, Atlanta, U.S.A., and national registers and scientific societies in which infectious complications derived from the use of biological therapies were mentioned.
  • Thumbnail Image
    Item
    Detección precoz de infección por citomegalovirus en pacientes sometidos a trasplante alogéneico de precursores hematopoyéticos por reacción de polimerasa en cadena cuantitativa en tiempo real
    (2014) Ceballos, María Elena; Vizcaya Altamirano, María Cecilia; Pavez, D.; Cerda, Jaime; Martínez Valdebenito, C.; Montecinos, L.; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
    (2021) Balcells Marty, Maria Elvira; Rojas Orellana, Luis Esteban; Martínez Valdebenito, Constanza Pamela; Ceballos Valdivielso, María Elena Andrea; Ferrés Garrido, Marcela Viviana; Chang Rathkamp, Mayling Raquel; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Huete Garín, Isidro Álvaro; Castro López, Ricardo Adolfo; Sarmiento Maldonado, Mauricio; Villarroel Del Pino, Luis Antonio; Pizarro Ibáñez, Alejandra Valentina; Ross Pérez, Patricio Daniel; Santander Toro, Jaime Andrés; Lara Hernández, Bárbara Alejandra; Ferrada Koch, Marcela Patricia; Vargas Salas, Sergio Sebastián; Beltrán Pávez, Carolina; Soto Rifo, Ricardo; Valiente Echeverria, Fernando Andrés; Caglevic, Christian; Mahave, Mauricio; Selman Bravo, Carolina Antoniett; Gazitúa, Raimundo; Briones, José Luis; Villarroel Espíndola, Franz; Balmaceda Araque, Carlos Felipe; Espinoza Sepúlveda, Manuel Antonio; Pereira Garces, Jaime; Nervi Nattero, Bruno; Le Corre Perez, Monique Nicole
    Background: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression.", "Methods and findings", "The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion.", "Conclusions", "In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.
  • Thumbnail Image
    Item
    Ecology, Genetic Diversity, and Phylogeographic Structure of Andes Virus in Humans and Rodents in Chile
    (2009) Medina, Rafael; Palma Vásquez, Ramón Eduardo; Ferrés Garrido, Marcela Viviana
  • No Thumbnail Available
    Item
    Endocarditis infecciosa por Bartonella. Descripción de dos casos en Chile
    (2019) Delama, Ignacio; Mondaca, Roberto; Aguayo, Ignacia; Roldán, Andrés; Ferrés Garrido, Marcela Viviana; Fica, Alberto
    Infectious endocarditis (IE) by Bartonella species is an emerging problem worldwide. We report two cases of native valve Bartonella-associated IE events, both affecting adult male patients with a history of alcohol abuse and a low socioeconomic status. Admissions were due to pancytopenia and bleeding in one case and embolic stroke in the other. Blood cultures were negative and IgG indirect immunofluorescence assays (IFA) were positive for B. henselae/B. quintana in high titers (1/16,384-1/16,384, and 1/32,768 -1/16,384, respectively). Cases were classified as definitive IE events according to modified Duke criteria due to the presence of valve vegetations with at least three minor criteria. One patient required aortic mechanical valve replacement and survived, and the other died after a massive hemorrhagic transformation of his stroke. PCR amplification and sequencing of the 16S ribosomal bacterial DNA from a valve tissue sample obtained at surgery in the patient who survived, confirmed B. quintana as the etiological agent. Bartonella-associated IE is an emerging problem in Chile, present in disadvantaged populations. It should be suspected in patients with culture-negative IE. IFA does not discriminate between B. henselae and B. quintana infection, but high titers suggest IE. Complementary PCR techniques may help to elucidate the final causative agent.
  • Thumbnail Image
    Item
    Estrategias para reducir infecciones, uso de antimicrobianos y sus efectos en una unidad de neonatología
    (2017) Urzúa Baquedano, María Soledad; Ferrés Garrido, Marcela Viviana; García Cañete, Patricia; Sánchez, Amparo; Luco Illanes, Matías Fernando
  • Thumbnail Image
    Item
    Evaluation of monoclonal antibodies that detect conserved proteins from Respiratory Syncytial Virus, Metapneumovirus and Adenovirus in human samples
    (2018) González Carreño, Liliana Andrea; Vazquez, Yaneisi; Mora, Jorge E.; Palavecino, Christian E.; Bertrand N., Pablo; Ferrés Garrido, Marcela Viviana; Contreras, Ana María; Beckhaus, Andrea A.; Riedel, Claudia; Bueno Ramírez, Susan
  • Thumbnail Image
    Item
    Exactitud y utilidad diagnóstica de la IgM en infecciones por Bartonella henselae
    (2013) Abarca Villaseca, Katia; Winter, Matías; Marsac, Delphine; Palma, Carlos; Contreras, Ana M.; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration
    (2016) Bugedo Tarraza, Guillermo; Florez, Jorge; Ferrés Garrido, Marcela Viviana; Roessler Barrón, Eric; Bruhn, Alejandro
  • Thumbnail Image
    Item
    Hantavirus: descripción de dos décadas de endemia y su letalidad
    (2018) Reyes Zaldivar, Felipe Tomás; Ferrés Garrido, Marcela Viviana
    Introducción: la infección por hantavirus es una zoonosis endémica en Chile. En dos décadas la letalidad ha descendido a una cifra estable de alrededor de un 30%, pese a importantes esfuerzos por disminuirla. Objetivos: describir los eventos que ocurren antes de la hospitalización y analizar la relación entre estas variables y la letalidad, con el objetivo de identificar momentos de intervención para mejorar la sobrevida de los pacientes. Material y Métodos: se analizaron retrospectivamente todos los casos notificados a través del Boletín Notificación Enfermedades de Declaración Obligatoria (ENO), la Encuesta Epidemiológica de Investigación Ambiental de los casos de Hantavirus del Ministerio de Salud de Chile. Resultados: existieron diferencias significativas en la letalidad por HV determinada por zona geográfica, tipo de trabajo y hospital donde se atendió primariamente el caso. Conclusiones: Hantavirus, por su rápida evolución hacia una condición catastrófica debe tenerse siempre presente en el diagnóstico diferencial y proceder en consecuencia para tener un diagnóstico precoz y acceso a un centro hospitalario con experiencia en manejo de esta patología.
  • Thumbnail Image
    Item
    Hantaviruses and cardiopulmonary syndrome in South America
    (2014) Figueiredo, L.; Souza, W.; Ferrés Garrido, Marcela Viviana; Enria, D.
  • Thumbnail Image
    Item
    High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile : a double-blind, randomized controlled clinical trial
    (2013) Vial, Pablo A.; Valdivieso, Francisca; Ferrés Garrido, Marcela Viviana; Riquelme, Raúl; Rioseco, M. Luisa; Calvo, Mario; Castillo, Constanza; Díaz, Ricardo; Scholz, Luis; Cuiza, Analia
  • Thumbnail Image
    Item
    HIV-1 tropism : a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients
    (2013) Ferrés Garrido, Marcela Viviana; Montecinos, Luisa; Tello, Mario; Tordecilla, Rocío; Rodríguez, Consuelo; Pérez, Carlos; Beltrán, Carlos; Guzmán Meléndez, María Antonieta; Afani Saud, Alejandro
  • Thumbnail Image
    Item
    Identification of biomarkers for disease severity in nasopharyngeal secretions of infants with upper or lower respiratory tract viral infections
    Bertrand N., Pablo; Vazquez, Yaneisi; Beckhaus, Andrea A.; González Carreño, Liliana Andrea; Contreras Sepúlveda, Ana María; Ferrés Garrido, Marcela Viviana; Padilla Pérez, Oslando; Riedel, Claudia A.; Kalergis Parra, Alexis Mikes; Bueno, Susan M.
    Lower respiratory tract infections (LRTIs) produced by viruses are the most frequent cause of morbidity and mortality in children younger than 5 years of age. The immune response triggered by viral infection can induce a strong inflammation in the airways and cytokines could be considered as biomarkers for disease severity as these molecules modulate the inflammatory response that defines the outcome of patients. Aiming to predict the severity of disease during respiratory tract infections, we conducted a 1-year follow-up observational study in infants who presented upper or lower respiratory tract infections caused by seasonal respiratory viruses. At the time of enrollment, nasopharyngeal swabs (NPS) were obtained from infants to measure mRNA expression and protein levels of IL-3, IL-8, IL-33, and thymic stromal lymphopoietin. While all cytokines significantly increased their protein levels in infants with upper and lower respiratory tract infections as compared to control infants, IL-33 and IL-8 showed a significant increase in respiratory syncytial virus (RSV)-infected patients with LRTI as compared to patients with upper respiratory tract infection. We also found higher viral loads of RSV-positive samples with a greater IL-8 response at the beginning of the symptoms. Data obtained in this study suggest that both IL-8 and IL-33 could be used as biomarkers for clinical severity for infants suffering from LRTIs caused by the RSV.
  • Thumbnail Image
    Item
    Infección del sitio quirúrgico en niños sometidos a cirugía cardíaca con cierre esternal diferido. Estudio de casos y controles
    (2016) Retamal, Javiera; Becker Rencoret, Pedro Antonio; González Foretic, Rodrigo Vicente; Ferrés Garrido, Marcela Viviana; Cerda, Jaime; Riquelme, María I.; Pérez, R.; Clavería Rodríguez, Cristian
  • Thumbnail Image
    Item
    Infecciones asociadas a la atención en salud (IAAS) en pacientes pediátricos post-operados de cardiopatías congénitas
    (2014) Barriga, J.; Cerda, Jaime; Abarca Villaseca, Katia; Ferrés Garrido, Marcela Viviana; Fajuri, P.; Riquelme, M.; Carrillo, D.; Clavería Rodríguez, Cristian